Published online before print April 19, 2007

This Article Full Text Full Text (PDF) Supplemental Material All Versions of this Article: ajpath.2007.060537v1 170/6/2089    most recent Purchase Article View Shopping Cart Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rittié, L. Articles by Elder, J. T. Search for Related Content PubMed Articles by Rittié, L. Articles by Elder, J. T.

(American Journal of Pathology. 2007;170:2089-2099.)
© 2007 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2007.060537

Differential ErbB1 Signaling in Squamous Cell versus Basal Cell Carcinoma of the Skin

Laure Rittié^*, Sanjay Kansra^*, Stefan W. Stoll^*, Yong Li^*, Johann E. Gudjonsson^*, Yuan Shao^*, Lowell E. Michael^*, Gary J. Fisher^*, Timothy M. Johnson^* and James T. Elder^*¶

From the Departments of Dermatology,^* Otolaryngology, Surgery, and Radiation Oncology, University of Michigan Medical Center, Ann Arbor; and the Ann Arbor Veterans Affairs Health System,^¶ Ann Arbor, Michigan

In this study, we examined ErbB1 signaling in human basal and squamous cell carcinomas (BCC and SCC) of the skin in vivo. We used enzyme-linked immunosorbent assay, laser capture microdissection-coupled real-time reverse transcriptase-polymerase chain reaction, and immunohistochemistry to assess expression and activation levels of ErbB1 protein, ligands, and potential downstream effectors, in BCC and SCC tumors, stroma, and adjacent epidermis. Although total ErbB1 protein and mRNA were similar in cancerous and normal skin, we found that ErbB1 activation (phospho-Tyr¹⁰⁶⁸) was greater in bulk SCC versus BCC or normal skin. In addition, three ErbB1 ligand transcripts (amphiregulin, heparin-binding epidermal growth factor-like growth factor, and transforming growth factor-) were up-regulated in tumor cells of SCC but not BCC. Expression of these ligands was also increased in asymptomatic epidermis adjacent to both SCC and BCC, relative to normal skin. Interestingly, betacellulin transcript levels were inversely regulated compared with the other ligands. Consistently, downstream ErbB1 effectors (Erk1/2 and Akt) were activated in tumor cells of SCC but not of BCC and in adjacent epidermis of both BCC and SCC. These results demonstrate that ErbB1 signaling is hyperactive in tumor cells of SCC but not of BCC and in nearby asymptomatic epidermis of both tumor types. Our results suggest that targeting ErbB1 signaling might be of benefit in the treatment of SCC.

This article has been cited by other articles:

				M. R. Schneider, S. Werner, R. Paus, and E. Wolf Beyond Wavy Hairs: The Epidermal Growth Factor Receptor and Its Ligands in Skin Biology and Pathology Am. J. Pathol., July 1, 2008; 173(1): 14 - 24. [Abstract] [Full Text] [PDF]

				A. J. Najy, K. C. Day, and M. L. Day The Ectodomain Shedding of E-cadherin by ADAM15 Supports ErbB Receptor Activation J. Biol. Chem., June 27, 2008; 283(26): 18393 - 18401. [Abstract] [Full Text] [PDF]

				G. W. Neill, W. J. Harrison, M. S. Ikram, T. D.L. Williams, L. S. Bianchi, S. K. Nadendla, J. L. Green, L. Ghali, A.-M. Frischauf, E. A. O'Toole, et al. GLI1 repression of ERK activity correlates with colony formation and impaired migration in human epidermal keratinocytes Carcinogenesis, April 1, 2008; 29(4): 738 - 746. [Abstract] [Full Text] [PDF]